Writing the Next Chapter in Precision Medicines

Discovering and developing the next generation of precision medicines through:

Industry leaders with a proven track record of success

Building a broad pipeline of potentially best-in-class therapies

News

July 2, 2026
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
May 5, 2026
OnKure Therapeutics Reports First Quarter 2026 Financial Results
March 27, 2026
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
View All News